Cargando…
Exploration of the Inhibitory Potential of Varespladib for Snakebite Envenomation
Phospholipase A(2)s (PLA(2)) is a major component of snake venom with diverse pathologic toxicities and, therefore, a potential target for antivenom therapy. Varespladib was initially designed as an inhibitor of mammal PLA(2)s, and was recently repurposed to a broad-spectrum inhibitor of PLA(2) in s...
Autores principales: | Wang, Yiding, Zhang, Jing, Zhang, Denghong, Xiao, Huixiang, Xiong, Shengwei, Huang, Chunhong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6017252/ https://www.ncbi.nlm.nih.gov/pubmed/29439513 http://dx.doi.org/10.3390/molecules23020391 |
Ejemplares similares
-
Correction: Wang et al. Exploration of the Inhibitory Potential of Varespladib for Snakebite Envenomation. Molecules 2018, 23, 391
por: Wang, Yiding, et al.
Publicado: (2022) -
The BRAVO Clinical Study Protocol: Oral Varespladib for Inhibition of Secretory Phospholipase A2 in the Treatment of Snakebite Envenoming
por: Carter, Rebecca W., et al.
Publicado: (2022) -
Varespladib in the Treatment of Snakebite Envenoming: Development History and Preclinical Evidence Supporting Advancement to Clinical Trials in Patients Bitten by Venomous Snakes
por: Lewin, Matthew R., et al.
Publicado: (2022) -
Inactivation of Venom PLA(2) Alleviates Myonecrosis and Facilitates Muscle Regeneration in Envenomed Mice: A Time Course Observation
por: Xiao, Huixiang, et al.
Publicado: (2018) -
Antibiotic therapy for snakebite envenoming
por: Resiere, Dabor, et al.
Publicado: (2020)